TISSUE ENGINEERING AND REGENERATION: TECHNOLOGIES AND GLOBAL MARKETS
|
|
- Robert Logan
- 6 years ago
- Views:
Transcription
1 TISSUE ENGINEERING AND REGENERATION: TECHNOLOGIES AND GLOBAL MARKETS HLC101B August 2014 Yojana Jeevane Project Analyst ISBN: BCC Research 49 Walnut Park, Building 2 Wellesley, MA USA (toll-free within the USA), or (+1) information@bccresearch.com
2 TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 2 STUDY AND OBJECTIVE 2 SCOPE OF THE REPORT 2 INTENDED AUDIENCE 3 INFORMATION AND METHODOLOGY SOURCES 3 ANALYST'S CREDENTIALS 3 RELATED BCC RESEARCH REPORTS 4 BCC RESEARCH WEBSITE 4 DISCLAIMER 4 CHAPTER 2 EXECUTIVE SUMMARY 6 SUMMARY TABLE GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY SUMMARY FIGURE GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, ($ 7 7 CHAPTER 3 TISSUE ENGINEERING AND REGENERATION 10 MARKET OVERVIEW 10 PROGRESS AND PROMISES FOR THE TISSUE ENGINEERING INDUSTRY 11 FIGURE 1 TISSUE-ENGINEERING STRATEGIES 12 REPLACING BODY PARTS THROUGH TISSUE ENGINEERING 13 NANOTECHNOLOGY FOR TISSUE REGENERATION 13 FIGURE 2 POTENTIAL NANOTECHNOLOGY APPLICATIONS 14 EFFECTS OF NANOTECHNOLOGY ON STEM CELL BEHAVIOUR FOR TISSUE REGENERATION Nanoparticles 14 Nanoscaffolds 15 NANOTECHNOLOGY IN TISSUE REGENERATION APPLICATIONS 15 Bone and Cartilage Regeneration 15 Vascular Tissue Regeneration 15 Neural Tissue Regeneration 15 GENE THERAPIES AS PART OF THE FUTURE OF TISSUE ENGINEERING 16 PROGRESS 16 PROSPECTS 17 STEM CELL TECHNOLOGIES BOON TO TISSUE ENGINEERING 17 GOVERNMENT REGULATIONS AND LEGISLATIONS 18 U.S. AND EUROPEAN REGULATION FOR TISSUE ENGINEERING PRODUCTS 18 CHINESE REGULATION FOR TISSUE ENGINEERING 19 REGULATORY DIFFERENCES 20 TABLE 1 REGULATORY APPROVAL DIFFERENCES BETWEEN THE U.S. AND EUROPE 21 ETHICAL ISSUES REGARDING STEM CELL THERAPIES AND CORD BLOOD BANKING Ethical Issues Regarding Cord Blood Banking 21 Ethical Issues in Cord Blood Stem Cell Therapies 22 IMPACT OF THE HEALTHCARE SYSTEM ON TISSUE ENGINEERING MARKET DEVELOPMENT
3 TABLE 2 HEALTHCARE PROVISIONS BY COUNTRY, PORTER'S FIVE FORCE ANALYSIS OF THE TISSUE ENGINEERING AND REGENERATION MARKET FIGURE 3 PORTER S FIVE FORCE MODEL FOR TISSUE ENGINEERING PRODUCTS 24 SUPPLIER BARGAINING POWER: MODERATE 24 BUYER BARGAINING POWER: LOW 25 THREATS FROM SUBSTITUTE PRODUCTS: LOW 25 THREATS FROM NEW ENTRANTS: HIGH 25 COMPETETION FROM INDUSTRY PLAYERS: HIGH 25 CLINICAL TRIALS 26 U.S. TISSUE ENGINEERING CLINICAL TRIALS 26 TABLE 3 U.S. CLINICAL TRIALS FOR TISSUE ENGINEERING 26 Completed Clinical Trials for Tissue Engineering 27 TABLE 4 U.S. CLINICAL TRIALS FOR TISSUE ENGINEERING 27 Conclusion 28 Terminated Clinical Trials for Tissue Engineering 29 TABLE 5 U.S. TERMINATED CLINICAL TRIALS 29 Conclusion 29 EUROPEAN CLINICAL TRIALS FOR TISSUE ENGINEERING 29 TABLE 6 EUROPEAN CLINICAL TRIALS FOR TISSUE ENGINEERING 30 Conclusion 30 MARKET DYNAMICS 31 DRIVERS 31 Emergence of Stem Cell Technology 31 FIGURE 4 GROWTH IN DISEASE TREATED VERSUS CLINICAL TRIALS, (NO. OF TRIALS AND TREATMENTS) Prominent Potential of Nanotechnology 32 Rise in Prevalence of Trauma Emergencies and Chronic Diseases 33 TABLE 7 U.S. UNINTENTIONAL INJURIES FACTS, 2013 (NO./%) 33 Advancement in Surgical Technologies and Monitoring Devices 33 TABLE 8 REGENERATIVE MEDICINE INDUSTRY TRENDS, RESTRAINTS 34 Operational Inefficiency 34 Stringent Regulatory Policies and Ethical Issues 35 High Treatment Cost 35 STEM CELL APPLICATION OPPORTUNITIES 35 Classification of Stem Cells According to Their Ability to Differentiate 36 Getting Core Competency in Emerging Economies CHAPTER 4 TISSUE ENGINEERING AND REGENERATION MARKET ANALYSIS BY TECHNOLOGY TABLE 9 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY TECHNOLOGY, STEM CELL TECHNOLOGIES 38 TABLE 10 GLOBAL STEM CELL TISSUE ENGINEERING AND REGENERATION MARKET BY STEM CELL SOURCES 40 STEM CELL EXTRACTION TECHNIQUES
4 ALTERED NUCLEAR TRANSFER 42 BLASTOMERE EXTRACTION 42 STEM CELL EXPANSION 42 STEM CELL DELIVERY 43 TABLE 11 COMMONLY USED VEHICLES FOR STEM CELL DELIVERY 44 Direct Surgical Intramyocardial Injection 44 EXISTING AND DEVELOPMENT-STAGE STEM CELL PRODUCTS 44 TABLE 12 COMMERCIALIZED TISSUE ENGINEERING PRODUCT SALES, 2011 ($ Clinical Application of Stem Cell Technologies in the Commercial Market Cardiovascular Repair 45 Neural Repair 45 Bone Repair 46 Skeletal Muscle Repair 46 Urologic Repair 46 CELL CULTURE TECHNOLOGIES 46 PROJECT NO Project Description 48 PROJECT NO Project Description 48 PROJECT NO Project Description 49 PROJECT NO Project Description 49 PROJECT NO Project Description 49 PROJECT NO Project Description 50 PROJECT NO Project Description 50 TABLE 13 GLOBAL CELL CULTURE TISSUE ENGINEERING AND REGENERATION MARKET BY IMMUNOPASSIVATION AND IMMUNOMODULATION 51 IMMUNOMODULATION 51 CELL ENCAPSULATION 52 TABLE 14 GLOBAL IMMUNOPASSIVATION AND IMMUNOMODULATION TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, THROUGH 2019 ($ CHAPTER 5 TISSUE ENGINEERING AND REGENERATION MARKET ANALYSIS BY MATERIALS TABLE 15 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY MATERIAL, SYNTHETIC MATERIALS 55 TABLE 16 GLOBAL SYNTHETIC TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY TYPE, TABLE 17 GLOBAL SYNTHETIC TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY
5 BIODEGRADABLE SYNTHETIC POLYMERS 56 TABLE 18 BIODEGRADABLE POLYMER CLASSIFICATION 57 TABLE 19 GLOBAL BIODEGRADABLE SYNTHETIC POLYMER MATERIAL MARKET BY MEDICAL POLY LACTIC ACID SCAFFOLD 58 TABLE 20 COMMERCIAL POLYMERIC SCAFFOLD PRODUCTS 59 TABLE 21 GLOBAL SCAFFOLD MATERIAL MARKET BY REGION, THROUGH 2019 ($ ARTIFICIAL VASCULAR GRAFT MATERIALS 60 Stem Cell Integration in Vascular Tissue Engineering 60 Extracellular Matrix ECM-Based Vascular Grafts 60 Cell Sheets without Scaffold Support 61 TABLE 22 GLOBAL ARTIFICIAL VASCULAR GRAFT MATERIAL MARKET BY REGION, HYDROGEL TECHNOLOGY 61 TABLE 23 GLOBAL HYDROGEL TECHNOLOGY MARKET BY REGION, THROUGH 2019 ($ BIOLOGICALLY DERIVED MATERIALS 62 TABLE 24 GLOBAL BIOLOGICALLY DERIVED TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY TYPE, TABLE 25 GLOBAL BIOLOGICALLY DERIVED TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY COLLAGEN 63 TABLE 26 GLOBAL BIOLOGICALLY DERIVED COLLAGEN MATERIAL MARKET BY TABLE 27 GLOBAL BIOLOGICALLY DERIVED COLLAGEN MATERIAL MARKET BY Animal-Derived 65 Recombinant 65 XENOGENIC TISSUE 65 TABLE 28 GLOBAL BIOLOGICALLY DERIVED XENOGENIC TISSUE MATERIAL MARKET BY GENETICALLY ENGINEERED MATERIALS 66 TABLE 29 GLOBAL GENETICALLY ENGINEERED MATERIAL MARKET BY TYPE, TABLE 30 GLOBAL GENETICALLY ENGINEERED MATERIAL MARKET BY REGION, DEOXYRIBONUCLEIC ACID TRANSFECTION VECTORS 67 TABLE 31 GLOBAL DEOXYRIBONUCLEIC ACID TRANSFECTION VECTOR MARKET BY GENETICALLY MANIPULATED CELLS 68 TABLE 32 GLOBAL GENETICALLY MANIPULATED CELL MARKET BY REGION, THREE-DIMENSIONAL POLYMER TECHNOLOGY 69 TABLE 33 GLOBAL THREE-DIMENSIONAL POLYMER TECHNOLOGY MARKET BY TRANGENICS 70 TABLE 34 GLOBAL TRANSGENIC TECHNOLOGY MARKET BY REGION, THROUGH 2019 ($ FIBROBLASTS
6 TABLE 35 GLOBAL FIBROBLAST MARKET BY 71 NEURAL STEM CELLS 71 TABLE 36 GLOBAL NEURAL STEM CELL MARKET BY REGION, THROUGH 2019 ($ GENE-ACTIVATED MATRICES 72 TABLE 37 GLOBAL GENE-ACTIVATED MATRIX MARKET BY REGION, THROUGH 2019 ($ CHAPTER 6 TISSUE ENGINEERING AND REGENERATION MARKET BY APPLICATION 75 TABLE 38 GLOBAL TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET BY TYPE, INTERNAL ORGAN REGENERATION 75 TABLE 39 GLOBAL INTERNAL ORGAN REGENERATION APPLICATION MARKET BY LIVER REGENERATION 76 TABLE 40 U.S. LIVER FAILURE STATISTICS, TABLE 41 ARTIFICIAL LIVER SUPPORT SYSTEMS 78 PANCREAS AND ISLET CELL REGENERATION 79 TABLE 42 U.S. PANCREATIC CANCER AND DIABETES STATISTICS, KIDNEY AND RENAL TUBULE REGENERATION 81 TABLE 43 U.S. KIDNEY DISEASE STATISTICS, ORTHOPEDIC APPLICATIONS 82 TABLE 44 KEY FACTS REGARDING ORTHOPEDIC DISEASES, BY REGION 82 TABLE 45 GLOBAL ORTHOPEDIC APPLICATION MARKET BY REGION, THROUGH 2019 ($ BONE REPAIR AND REPLACEMENT 83 TABLE 46 BONE DAMAGE AND RELATED DISEASES, 2011 ( 84 CARTILAGE AND CONNECTIVE TISSUE DAMAGE TREATMENT 84 TISSUE-ENGINEERED PRODUCTS FOR BONE DEFECTS 85 CARTILAGE REPAIR AND REPLACEMENT 87 TABLE 47 GLOBAL CARTILAGE DAMAGE STATISTICS, MENISCUS REPAIR AND REPLACEMENT 88 TENDON AND LIGAMENT REPAIR AND REPLACEMENT 88 TISSUE ENGINEERING FOR THE CENTRAL NERVOUS SYSTEM 89 TISSUE ENGINEERING FOR CENTRAL NERVOUS SYSTEM DISEASES 90 TABLE 48 GLOBAL TISSUE ENGINEERING FOR CENTRAL NERVOUS SYSTEM APPLICATION MARKET BY NEUROSURGICAL 91 Cell Implants for Parkinson's Diseases 92 TABLE 49 GLOBAL NEURODEGENERATIVE DISEASE STATISTICS, Cell Transplants for Epilepsy Treatment 93 Stem Cell Therapy for Multiple Sclerosis 93 SPINAL CORD INJURY AND SPINAL DISC REPAIR AND REPLACEMENT 94 TABLE 50 GLOBAL SPINAL CORD INJURY STATISTICS, Spinal Cord Injury Treatments 94 Tissue Engineering for Spinal Cord Injury 95 Cell Therapy for Spinal Cord Injury 95 Scaffold Approach for Spinal Cord Injury Treatment 96 TISSUE ENGINEERING FOR CARDIOVASCULAR DISORDERS
7 TABLE 51 GLOBAL CARDIOVASCULAR DISORDERS APPLICATION MARKET BY PERIPHERAL VASCULAR DISEASE APPLICATIONS 98 CORONARY ARTERY DISEASE APPLICATIONS 99 Heart Valves and Tissue Engineering 100 Mechanical Heart Valves 100 Biological Heart Valves 100 TABLE 52 COMPANIES DEVELOPING CELL THERAPIES FOR CARDIO VASCULAR DISORDERS, 2013 DENTAL TISSUE ENGINEERING 102 TABLE 53 GLOBAL DENTAL TISSUE ENGINEERING APPLICATION MARKET BY DERMATOLOGY TISSUE ENGINEERING 103 TABLE 54 U.S. AND GLOBAL SKIN DAMAGE MEDICAL CONDITION STATISTICS, TABLE 55 COMMERCIALIZED ACELLULAR SKIN TISSUE-ENGINEERED, TABLE 56 COMMERCIALIZED CELLULAR SKIN TISSUE ENGINEERED PRODUCTS 105 TABLE 57 GLOBAL DERMATOLOGY TISSUE ENGINEERING APPLICATION MARKET BY WOUND MANAGEMENT 107 TABLE 58 WOUND CARE MARKET BY CATEGORY (%) 107 Burn Treatment 108 Ulcer Treatment 109 ANTI-AGING THERAPIES 110 OTHERS 110 TABLE 59 GLOBAL OTHER APPLICATION MARKET BY REGION, THROUGH 2019 ($ MUSCLE REGENERATION 110 TABLE 60 IN VITRO VERSUS IN VIVO SKELETAL MUSCLE TISSUE ENGINEERING 111 PERIPHERAL NERVE REPAIR 112 HERNIA AND SOFT TISSUE REPAIR CHAPTER 7 TISSUE ENGINEERING AND REGENERATION MARKET BY REGION 114 TABLE 61 COMPANIES OPERATING IN REGENERATIVE MEDICINES MARKET BY CONTINENT, 2011 ($ TABLE 62 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, NORTH AMERICA 115 TABLE 63 NORTH AMERICAN COMMERCIALIZED TISSUE ENGINEERING PRODUCTS, 2013 TABLE 64 NORTH AMERICAN TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, U.S. SKIN TISSUE ENGINEERING PRODUCT MARKET 119 TABLE 65 U.S. SKIN DAMAGE CONDITIONS REQUIRING WOUND CARE, U.S. CARTILAGE AND BONE TISSUE ENGINEERING PRODUCT MARKET 120 TABLE 66 U.S. BONE DAMAGE AND RELATED DISEASE STATISTICS, U.S. TISSUE ENGINEERING PRODUCTS FOR CARDION VASCULAR DISORDERS MARKET TABLE 67 U.S. CARDIOVASCULAR DISORDER STATISTICS, 2010 AND EUROPE
8 TABLE 68 TISSUE ENGINEERING FIRMS BY TYPE, 2012 (%) 122 TABLE 69 EUROPEAN TISSUE ENGINEERING FIRMS BY REGION, 2012 (%) 123 TABLE 70 EUROPEAN SKIN DAMAGE CONDITIONS REQUIRING WOUND CARE STATISTICS, 2011 TABLE 71 EUROPEAN COMPANIES SELLING OR DEVELOPING SKIN TISSUE-ENGINEERED PRODUCTS, 2013 TABLE 72 EUROPEAN TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, EUROPEAN AND BONE TISSUE ENGINEERING PRODUCT MARKET 126 TABLE 73 EUROPEAN BONE DAMAGE AND RELATED DISEASE MARKET BY COUNTRY EUROPEAN TISSUE ENGINEERING PRODUCTS FOR CARDIOVASCULAR DISORDERS MARKET TABLE 74 EUROPEAN CARDIOVASCULAR DISORDER STATISTICS, TABLE 75 EUROPEAN RATE OF DEATH FROM HEART DISEASE BY COUNTRY, 2011 (DEATHS PER 100,000 CASES) EUROPEAN TISSUE ENGINEERING PRODUCTS FOR CENTRAL NERVOUS SYSTEM-RELATED INJURIES AND DISORDERS MARKET TABLE 76 EUROPEAN CENTRAL NERVOUS SYSTEM DISORDERS AND INJURIES, TABLE 77 EUROPEAN SPINAL CORD INJURY AND PARKINSON'S DISEASE BY COUNTRY, 2011 TABLE 78 EUROPEAN STEM CELL POLICIES BY COUNTRY, 130 TABLE 79 EUROPEAN COMPANIES DEVELOPING PRODUCTS IN TISSUE ENGINEERING AND REGENERATION FOR CENTRAL NERVOUS SYSTEM DISORDERS AND INJURIES EUROPEAN TISSUE ENGINEERING FOR INTERNAL ORGANS MARKET 131 ASIA-PACIFIC 132 FIGURE 5 PATHWAY FOR DISSEMINATION OF REGENERATIVE MEDICINE 133 TABLE 80 ASIA-PACIFIC TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, ASIA-PACIFIC CARTILAGE AND BONE TISSUE ENGINEERING PRODUCT MARKET ASIA-PACIFIC MARKET FOR CARDIOVASCULAR TISSUE ENGINEERING PRODUCTS ASIA-PACIFIC SKIN TISSUE ENGINEERING PRODUCT MARKET 134 REST OF THE WORLD 135 TABLE 81 GLOBAL SKIN-RELATED MEDICAL CONDITION STATISTICS, TABLE 82 REST OF WORLD TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, REST OF THE WORLD CARTILAGE AND BONE TISSUE ENGINEERING PRODUCT MARKET REST OF WORLD TISSUE ENGINEERING PRODUCTS FOR CARDIOVASCULAR DISORDERS MARKET TABLE 83 GLOBAL CARDIOVASCULAR DISORDER STATISTICS, TABLE 84 REST OF THE WORLD COMPANIES THAT MANUFACTURE AND DEVELOP TISSUE-ENGINEERED PRODUCTS FOR CARDIOVASCULAR DISORDER, BY COUNTRY REST OF THE WORLD TISSUE ENGINEERING PRODUCTS FOR CENTRAL NERVOUS SYSTEM-RELATED INJURIES AND DISEASES MARKET TABLE 85 GLOBAL CENTRAL NERVOUS SYSTEM DISORDER AND INJURY STATISTICS,
9 CHAPTER 8 COMPETITIVE LANDSCAPE 142 FIGURE 6 KEY COMPETITIVE STRATEGIES*, (%) 142 TABLE 86 KEY COMPETITIVE STRATEGIES, (%) 143 APPROVAL 143 FIGURE 7 APPROVAL STRATEGY BY COMPANY, (%) 144 TABLE 87 APPROVAL STRATEGIES BY COMPANY, (NO./%) 145 TABLE 88 KEY APPROVALS, AGREEMENTS, MERGERS AND ACQUISITIONS 146 FIGURE 8 AGREEMENTS, MERGERS AND ACQUISITIONS, BY COMPANY, (%) TABLE 89 AGREEMENTS, MERGERS AND ACQUISITIONS BY COMPANY, (%) TABLE 90 KEY AGREEMENTS, MERGERS AND ACQUISITIONS, PRODUCT LAUNCHES AND CLINICAL TRIALS 149 FIGURE 9 PRODUCT LAUNCHES AND CLINICAL TRIALS BY COMPANY, (%) 150 TABLE 91 PRODUCT LAUNCHES AND CLINICAL TRIALS BY COMPANY, (%) 151 TABLE 92 KEY AGREEMENTS, MERGERS AND ACQUISITIONS, 2010 AND CHAPTER 9 PATENT ANALYSIS 153 TABLE 93 REGISTERED AND APPROVED PATENTS BY COUNTRY, (%) 153 FIGURE 10 REGISTERED AND APPROVED PATENTS BY COUNTRY, (%) 153 U.S. PATENT ANALYSIS BY MARKET PARTICIPANT 154 TABLE 94 U.S. PATENT ANALYSIS BY MARKET PARTICIPANT, (%) 154 FIGURE 11 U.S. PATENT ANALYSIS BY MARKET PARTICIPANT, (%) 154 U.S. PATENT ANALYSIS BY APPLICATIONS 155 TABLE 95 U.S. PATENT ANALYSIS BY APPLICATION, (%) 155 FIGURE 12 U.S. PATENT ANALYSIS BY APPLICATION, (%) 155 EUROPEAN PATENT ANALYSIS BY MARKET PARTICIPANT 156 TABLE 96 EUROPEAN PATENT ANALYSIS BY MARKET PARTICIPANT, (%) 156 FIGURE 13 EUROPEAN PATENT ANALYSIS BY MARKET PARTICIPANT, (%) 156 EUROPEAN PATENT ANALYSIS BY APPLICATIONS 157 TABLE 97 EUROPEAN PATENT ANALYSIS BY APPLICATION, (%) 158 FIGURE 14 EUROPEAN PATENT ANALYSIS BY APPLICATION, (%) 158 JAPANESE PATENT ANALYSIS BY APPLICATION 158 TABLE 98 JAPANESE PATENT ANALYSIS BY APPLICATION, (%) 159 FIGURE 15 JAPANESE PATENT ANALYSIS BY APPLICATION, (%) 159 CHAPTER 10 COMPANY PROFILES 161 ADVANCED BIOHEALING (A SHIRE PHARMACEUTICAL COMPANY) 161 TISSUE ENGINEERING PRODUCT PORTFOLIO 161 TABLE 99 ADVANCED BIOHEALING RECENT DEVELOPMENTS 162 TABLE 100 ADVANCED BIOHEALING FINANCIALS, ($ MILLIONS/%) 162 ADVANCED CELL TECHNOLOGY INC. 162 TISSUE ENGINEERING PRODUCT PORTFOLIO 163 TABLE 101 ADVANCED CELL TECHNOLOGY INC. RECENT DEVELOPMENTS 163 ARTERIOCYTE 163 TISSUE ENGINEERING PRODUCT PORTFOLIO 163 TABLE 102 ARTERIOCYTE RECENT DEVELOPMENTS 164
10 ATHERSYS INC. 164 TISSUE ENGINEERING PRODUCT PORTFOLIO 164 TABLE 103 ATHERSYS INC. RECENT DEVELOPMENTS 165 TABLE 104 ATHERSYS FINANCIALS, ($ MILLIONS/%) 165 BIOHEART INC. 165 TISSUE ENGINEERING PRODUCT PORTFOLIO 166 TABLE 105 BIOHEART INC. RECENT DEVELOPMENTS 166 CERAPEDICS INC. 166 TISSUE ENGINEERING PRODUCT PORTFOLIO 167 TABLE 106 CERAPEDICS INC. RECENT DEVELOPMENTS 167 CO.DON AG 167 TISSUE ENGINEERING PRODUCT PORTFOLIO 168 TABLE 107 CO.DON AG RECENT DEVELOPMENTS 168 COOK MEDICAL INC. 168 TISSUE ENGINEERING PRODUCT PORTFOLIO 169 TABLE 108 COOK MEDICAL INC. RECENT DEVELOPMENTS 169 CRYOLIFE INC 169 TISSUE ENGINEERING PRODUCT PORTFOLIO 169 TABLE 109 CRYO LIFE INC. RECENT DEVELOPMENTS 170 CYTOGRAFT TISSUE ENGINEERING 170 TISSUE ENGINEERING PRODUCT PORTFOLIO 170 TABLE 110 CYTOGRAFT TISSUE ENGINEERING RECENT DEVELOPMENTS 171 CYTOMEDIX INC. 171 TISSUE ENGINEERING PRODUCT PORTFOLIO 171 TABLE 111 CYTOMEDIX INC. RECENT DEVELOPMENTS 172 CYTORI THERAPEUTICS INC. 172 TISSUE ENGINEERING PRODUCT PORTFOLIO 172 TABLE 112 CYTORI THERAPEUTICS INC. RECENT DEVELOPMENTS 173 TABLE 113 CYTORI THERAPEUTICS FINANCIALS, ($ MILLIONS/%) 173 GENZYME (A SANOFI COMPANY) 173 TISSUE ENGINEERING PRODUCT PORTFOLIO 174 TABLE 114 GENZYME RECENT DEVELOPMENTS 174 TABLE 115 GENZYME FINANCIALS, ($ MILLIONS/%) 174 KINETIC CONCEPTS INC. 174 TISSUE ENGINEERING PRODUCT PORTFOLIO 175 TABLE 116 KINETIC CONCEPTS INC. RECENT DEVELOPMENTS 175 TABLE 117 KINETICS CONCEPTS FINANCIALS, ($ MILLIONS/%) 175 MESOBLAST LTD. 176 TISSUE ENGINEERING PRODUCT PORTFOLIO 176 ORGANOGENESIS INC. 176 TISSUE ENGINEERING PRODUCT PORTFOLIO 176 ORTHOPEUTICS 177 WRIGHT MEDICAL TECHNOLOGY INC. 177 TISSUE ENGINEERING PRODUCT PORTFOLIO 177 TABLE 118 WRIGHT MEDICAL TECHNOLOGY INC. RECENT DEVELOPMENTS 178 TABLE 119 WRIGHT MEDICAL TECHNOLOGY FINANCIALS, ($ MILLIONS/%) 178
11 CHAPTER 11 PATENTS 180 TABLE 120 NORTH AMERICAN PATENTS 180 TABLE 121 EUROPEAN PATENTS 181 TABLE 122 JAPANESE PATENTS 182
12 LIST OF TABLES TABLE HEADING SUMMARY TABLE GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY TABLE 1 REGULATORY APPROVAL DIFFERENCES BETWEEN THE U.S. AND EUROPE 21 TABLE 2 HEALTHCARE PROVISIONS BY COUNTRY, TABLE 3 U.S. CLINICAL TRIALS FOR TISSUE ENGINEERING 26 TABLE 4 U.S. CLINICAL TRIALS FOR TISSUE ENGINEERING 27 TABLE 5 U.S. TERMINATED CLINICAL TRIALS 29 TABLE 6 EUROPEAN CLINICAL TRIALS FOR TISSUE ENGINEERING 30 TABLE 7 U.S. UNINTENTIONAL INJURIES FACTS, 2013 (NO./%) 33 TABLE 8 REGENERATIVE MEDICINE INDUSTRY TRENDS, TABLE 9 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY TECHNOLOGY, TABLE 10 GLOBAL STEM CELL TISSUE ENGINEERING AND REGENERATION MARKET BY TABLE 11 COMMONLY USED VEHICLES FOR STEM CELL DELIVERY 44 TABLE 12 COMMERCIALIZED TISSUE ENGINEERING PRODUCT SALES, 2011 ($ TABLE 13 GLOBAL CELL CULTURE TISSUE ENGINEERING AND REGENERATION MARKET BY TABLE 14 GLOBAL IMMUNOPASSIVATION AND IMMUNOMODULATION TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, THROUGH 2019 ($ TABLE 15 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY MATERIAL, TABLE 16 GLOBAL SYNTHETIC TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY TYPE, TABLE 17 GLOBAL SYNTHETIC TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY TABLE 18 BIODEGRADABLE POLYMER CLASSIFICATION 57 TABLE 19 GLOBAL BIODEGRADABLE SYNTHETIC POLYMER MATERIAL MARKET BY TABLE 20 COMMERCIAL POLYMERIC SCAFFOLD PRODUCTS 59 TABLE 21 GLOBAL SCAFFOLD MATERIAL MARKET BY REGION, THROUGH 2019 ($ TABLE 22 GLOBAL ARTIFICIAL VASCULAR GRAFT MATERIAL MARKET BY REGION, TABLE 23 GLOBAL HYDROGEL TECHNOLOGY MARKET BY REGION, THROUGH 2019 ($ TABLE 24 GLOBAL BIOLOGICALLY DERIVED TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY TYPE, TABLE 25 GLOBAL BIOLOGICALLY DERIVED TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY TABLE 26 GLOBAL BIOLOGICALLY DERIVED COLLAGEN MATERIAL MARKET BY TABLE 27 GLOBAL BIOLOGICALLY DERIVED COLLAGEN MATERIAL MARKET BY TABLE 28 GLOBAL BIOLOGICALLY DERIVED XENOGENIC TISSUE MATERIAL MARKET BY TABLE 29 GLOBAL GENETICALLY ENGINEERED MATERIAL MARKET BY TYPE,
13 TABLE HEADING TABLE 30 GLOBAL GENETICALLY ENGINEERED MATERIAL MARKET BY REGION, TABLE 31 GLOBAL DEOXYRIBONUCLEIC ACID TRANSFECTION VECTOR MARKET BY TABLE 32 GLOBAL GENETICALLY MANIPULATED CELL MARKET BY REGION, TABLE 33 GLOBAL THREE-DIMENSIONAL POLYMER TECHNOLOGY MARKET BY TABLE 34 GLOBAL TRANSGENIC TECHNOLOGY MARKET BY REGION, THROUGH 2019 ($ TABLE 35 GLOBAL FIBROBLAST MARKET BY 71 TABLE 36 GLOBAL NEURAL STEM CELL MARKET BY REGION, THROUGH 2019 ($ TABLE 37 GLOBAL GENE-ACTIVATED MATRIX MARKET BY REGION, THROUGH 2019 ($ TABLE 38 GLOBAL TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET BY TYPE, TABLE 39 GLOBAL INTERNAL ORGAN REGENERATION APPLICATION MARKET BY TABLE 40 U.S. LIVER FAILURE STATISTICS, TABLE 41 ARTIFICIAL LIVER SUPPORT SYSTEMS 78 TABLE 42 U.S. PANCREATIC CANCER AND DIABETES STATISTICS, TABLE 43 U.S. KIDNEY DISEASE STATISTICS, TABLE 44 KEY FACTS REGARDING ORTHOPEDIC DISEASES, BY REGION 82 TABLE 45 GLOBAL ORTHOPEDIC APPLICATION MARKET BY REGION, THROUGH 2019 ($ TABLE 46 BONE DAMAGE AND RELATED DISEASES, 2011 ( 84 TABLE 47 GLOBAL CARTILAGE DAMAGE STATISTICS, TABLE 48 GLOBAL TISSUE ENGINEERING FOR CENTRAL NERVOUS SYSTEM APPLICATION MARKET BY TABLE 49 GLOBAL NEURODEGENERATIVE DISEASE STATISTICS, TABLE 50 GLOBAL SPINAL CORD INJURY STATISTICS, TABLE 51 GLOBAL CARDIOVASCULAR DISORDERS APPLICATION MARKET BY REGION, TABLE 52 COMPANIES DEVELOPING CELL THERAPIES FOR CARDIO VASCULAR DISORDERS, 2013 TABLE 53 GLOBAL DENTAL TISSUE ENGINEERING APPLICATION MARKET BY REGION, TABLE 54 U.S. AND GLOBAL SKIN DAMAGE MEDICAL CONDITION STATISTICS, TABLE 55 COMMERCIALIZED ACELLULAR SKIN TISSUE-ENGINEERED, TABLE 56 COMMERCIALIZED CELLULAR SKIN TISSUE ENGINEERED PRODUCTS 105 TABLE 57 GLOBAL DERMATOLOGY TISSUE ENGINEERING APPLICATION MARKET BY TABLE 58 WOUND CARE MARKET BY CATEGORY (%) 107 TABLE 59 GLOBAL OTHER APPLICATION MARKET BY REGION, THROUGH 2019 ($ TABLE 60 IN VITRO VERSUS IN VIVO SKELETAL MUSCLE TISSUE ENGINEERING 111 TABLE 61 COMPANIES OPERATING IN REGENERATIVE MEDICINES MARKET BY CONTINENT, 2011 ($ TABLE 62 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY REGION,
14 TABLE HEADING TABLE 63 NORTH AMERICAN COMMERCIALIZED TISSUE ENGINEERING PRODUCTS, 2013 TABLE 64 NORTH AMERICAN TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, TABLE 65 U.S. SKIN DAMAGE CONDITIONS REQUIRING WOUND CARE, TABLE 66 U.S. BONE DAMAGE AND RELATED DISEASE STATISTICS, TABLE 67 U.S. CARDIOVASCULAR DISORDER STATISTICS, 2010 AND TABLE 68 TISSUE ENGINEERING FIRMS BY TYPE, 2012 (%) 122 TABLE 69 EUROPEAN TISSUE ENGINEERING FIRMS BY REGION, 2012 (%) 123 TABLE 70 EUROPEAN SKIN DAMAGE CONDITIONS REQUIRING WOUND CARE STATISTICS, 2011 TABLE 71 EUROPEAN COMPANIES SELLING OR DEVELOPING SKIN TISSUE-ENGINEERED PRODUCTS, 2013 TABLE 72 EUROPEAN TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, TABLE 73 EUROPEAN BONE DAMAGE AND RELATED DISEASE MARKET BY COUNTRY 126 TABLE 74 EUROPEAN CARDIOVASCULAR DISORDER STATISTICS, TABLE 75 EUROPEAN RATE OF DEATH FROM HEART DISEASE BY COUNTRY, 2011 (DEATHS PER 100,000 CASES) TABLE 76 EUROPEAN CENTRAL NERVOUS SYSTEM DISORDERS AND INJURIES, TABLE 77 EUROPEAN SPINAL CORD INJURY AND PARKINSON'S DISEASE BY COUNTRY, 2011 TABLE 78 EUROPEAN STEM CELL POLICIES BY COUNTRY, 130 TABLE 79 EUROPEAN COMPANIES DEVELOPING PRODUCTS IN TISSUE ENGINEERING AND REGENERATION FOR CENTRAL NERVOUS SYSTEM DISORDERS AND INJURIES TABLE 80 ASIA-PACIFIC TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, TABLE 81 GLOBAL SKIN-RELATED MEDICAL CONDITION STATISTICS, TABLE 82 REST OF WORLD TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, TABLE 83 GLOBAL CARDIOVASCULAR DISORDER STATISTICS, TABLE 84 REST OF THE WORLD COMPANIES THAT MANUFACTURE AND DEVELOP TISSUE-ENGINEERED PRODUCTS FOR CARDIOVASCULAR DISORDER, BY COUNTRY TABLE 85 GLOBAL CENTRAL NERVOUS SYSTEM DISORDER AND INJURY STATISTICS, 2011 TABLE 86 KEY COMPETITIVE STRATEGIES, (%) 143 TABLE 87 APPROVAL STRATEGIES BY COMPANY, (NO./%) 145 TABLE 88 KEY APPROVALS, TABLE 89 AGREEMENTS, MERGERS AND ACQUISITIONS BY COMPANY, (%) 148 TABLE 90 KEY AGREEMENTS, MERGERS AND ACQUISITIONS, TABLE 91 PRODUCT LAUNCHES AND CLINICAL TRIALS BY COMPANY, (%) 151 TABLE 92 KEY AGREEMENTS, MERGERS AND ACQUISITIONS, 2010 AND TABLE 93 REGISTERED AND APPROVED PATENTS BY COUNTRY, (%) 153 TABLE 94 U.S. PATENT ANALYSIS BY MARKET PARTICIPANT, (%) 154 TABLE 95 U.S. PATENT ANALYSIS BY APPLICATION, (%) 155 TABLE 96 EUROPEAN PATENT ANALYSIS BY MARKET PARTICIPANT, (%) 156 TABLE 97 EUROPEAN PATENT ANALYSIS BY APPLICATION, (%) 158 TABLE 98 JAPANESE PATENT ANALYSIS BY APPLICATION, (%) 159 TABLE 99 ADVANCED BIOHEALING RECENT DEVELOPMENTS 162 TABLE 100 ADVANCED BIOHEALING FINANCIALS, ($ MILLIONS/%)
15 TABLE HEADING TABLE 101 ADVANCED CELL TECHNOLOGY INC. RECENT DEVELOPMENTS 163 TABLE 102 ARTERIOCYTE RECENT DEVELOPMENTS 164 TABLE 103 ATHERSYS INC. RECENT DEVELOPMENTS 165 TABLE 104 ATHERSYS FINANCIALS, ($ MILLIONS/%) 165 TABLE 105 BIOHEART INC. RECENT DEVELOPMENTS 166 TABLE 106 CERAPEDICS INC. RECENT DEVELOPMENTS 167 TABLE 107 CO.DON AG RECENT DEVELOPMENTS 168 TABLE 108 COOK MEDICAL INC. RECENT DEVELOPMENTS 169 TABLE 109 CRYO LIFE INC. RECENT DEVELOPMENTS 170 TABLE 110 CYTOGRAFT TISSUE ENGINEERING RECENT DEVELOPMENTS 171 TABLE 111 CYTOMEDIX INC. RECENT DEVELOPMENTS 172 TABLE 112 CYTORI THERAPEUTICS INC. RECENT DEVELOPMENTS 173 TABLE 113 CYTORI THERAPEUTICS FINANCIALS, ($ MILLIONS/%) 173 TABLE 114 GENZYME RECENT DEVELOPMENTS 174 TABLE 115 GENZYME FINANCIALS, ($ MILLIONS/%) 174 TABLE 116 KINETIC CONCEPTS INC. RECENT DEVELOPMENTS 175 TABLE 117 KINETICS CONCEPTS FINANCIALS, ($ MILLIONS/%) 175 TABLE 118 WRIGHT MEDICAL TECHNOLOGY INC. RECENT DEVELOPMENTS 178 TABLE 119 WRIGHT MEDICAL TECHNOLOGY FINANCIALS, ($ MILLIONS/%) 178 TABLE 120 NORTH AMERICAN PATENTS 180 TABLE 121 EUROPEAN PATENTS 181 TABLE 122 JAPANESE PATENTS 182
16 LIST OF FIGURES FIGURE TITLE SUMMARY FIGURE GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, ($ FIGURE 1 TISSUE-ENGINEERING STRATEGIES 12 FIGURE 2 POTENTIAL NANOTECHNOLOGY APPLICATIONS 14 FIGURE 3 PORTER S FIVE FORCE MODEL FOR TISSUE ENGINEERING PRODUCTS 24 FIGURE 4 GROWTH IN DISEASE TREATED VERSUS CLINICAL TRIALS, (NO. OF TRIALS AND TREATMENTS) FIGURE 5 PATHWAY FOR DISSEMINATION OF REGENERATIVE MEDICINE 133 FIGURE 6 KEY COMPETITIVE STRATEGIES*, (%) 142 FIGURE 7 APPROVAL STRATEGY BY COMPANY, (%) 144 FIGURE 8 AGREEMENTS, MERGERS AND ACQUISITIONS, BY COMPANY, (%) 147 FIGURE 9 PRODUCT LAUNCHES AND CLINICAL TRIALS BY COMPANY, (%) 150 FIGURE 10 REGISTERED AND APPROVED PATENTS BY COUNTRY, (%) 153 FIGURE 11 U.S. PATENT ANALYSIS BY MARKET PARTICIPANT, (%) 154 FIGURE 12 U.S. PATENT ANALYSIS BY APPLICATION, (%) 155 FIGURE 13 EUROPEAN PATENT ANALYSIS BY MARKET PARTICIPANT, (%) 156 FIGURE 14 EUROPEAN PATENT ANALYSIS BY APPLICATION, (%) 158 FIGURE 15 JAPANESE PATENT ANALYSIS BY APPLICATION, (%)
INUED DISCONTINUED DISCONTINUED DISCON MAKING THE IMPOSSIBLE POSSIBLE CENTER FOR REGENERATIVE MEDICINE
INUED DISCONTINUED DISCONTINUED DISCON MAKING THE IMPOSSIBLE POSSIBLE CENTER FOR > SOLUTIONS AND HOPE Millions of people worldwide suffer from deadly diseases, chronic conditions and congenital disorders
More informationUNIT CELL PROCESSES UNDERLYING TISSUE ENGINEERING AND REGENERATIVE MEDICINE
Massachusetts Institute of Technology Harvard Medical School Brigham and Women s Hospital VA Boston Healthcare System 2.79J/3.96J/20.441/HST522J UNIT CELL PROCESSES UNDERLYING TISSUE ENGINEERING AND REGENERATIVE
More informationSTENTS: TECHNOLOGIES AND GLOBAL MARKETS
STENTS: TECHNOLOGIES AND GLOBAL MARKETS HLC155A January 2015 Himani Singhi Wadhwa Project Analyst ISBN: 1-62296-020-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationTissue Engineered Medical Products
WORKSHOP 8 Tissue Organizer: Jeremy J. Rawlinson PhD Speakers: Jack E. Lemons, PhD Lawrence J. Bonassar, PhD Mauro R. Alini, PhD Michael J. Yaszemski, MD, PhD Standards for Tissue J. Lemons, University
More informationMEDICAL DEVICES: TECHNOLOGIES AND GLOBAL MARKETS
MEDICAL DEVICES: TECHNOLOGIES AND GLOBAL MARKETS HLC170B January 2017 Vijay Laxmi Project Analyst ISBN: 1-62296-410-1 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationDes cellules-souches dans le poumon : pourquoi faire?
Des cellules-souches dans le poumon : pourquoi faire? Karl-Heinz Krause Dept. of Pathology and Immunology, Medical Faculty Dept. of Genetic and Laboratory Medicine, University Hospitals Geneva, Switzerland
More informationThe Role of Adult Stem Cells in Personalized and Regenerative Medicine
The Role of Adult Stem Cells in Personalized and Regenerative Medicine Christopher J. Neill, Director of Corporate Operations American CryoStem Corporation Objective To illustrate the potential benefits
More informationCENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationGermany Tissue Engineered - Skin Substitutes Market Outlook to 2020
Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020 Reference Code: GDMECC0884DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More informationRENAL DIALYSIS EQUIPMENT: TECHNOLOGIES AND GLOBAL MARKETS
RENAL DIALYSIS EQUIPMENT: TECHNOLOGIES AND GLOBAL MARKETS HLC164A March 2014 Krishanu Bhattacharjee Project Analyst ISBN: 1-56965-744-0 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationBIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
: TECHNOLOGIES AND GLOBAL MARKETS BIO061C April 2014 Jackson Highsmith Project Analyst ISBN: 1-56965-801-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within
More informationEuropean Regenerative Medicine Firms & Their Strategic Approaches. Michael Morrison University of York
European Regenerative Medicine Firms & Their Strategic Approaches Michael Morrison University of York OVERVIEW Creating the European RM Universe of firms Characterizing the European RM Universe Strategic
More informationNEXT GENERATION ECM-BASED ALLOGRAFT TECHNOLOGY:
NEXT GENERATION ECM-BASED ALLOGRAFT TECHNOLOGY: Potent biological scaffolds strategically control stem cell fate and function, allowing our allografts to harness the regenerative potential of patient s
More informationRegenerative Medicine. Speaker Disclosures. What is regenerative medicine? 6/22/2016
Regenerative Medicine Halland Chen, MD Speaker Disclosures I disclose that I am not a consultant or have any financial interests. 2 What is regenerative medicine? Regeneration of human cells, tissues,
More informationISSCR 2017 Abstract Submission Guide
ISSCR 2017 Abstract Submission Guide The International Society for Stem Cell Research (ISSCR) invites the submission of abstracts that report new research developments across the breadth of stem cell biology,
More informationFrom Stem Cell to Any Cell
sciencenewsforkids.org http://www.sciencenewsforkids.org/2005/10/from-stem-cell-to-any-cell-2/ From Stem Cell to Any Cell By Emily Sohn / October 11, 2005 For maybe a day, about 9 months before you were
More information8 th Regenerative Medicine and Stem Cells
8 th Regenerative Medicine and Stem Cells Theme: Light the Hope of Incurable Diseases March 19 21, 2 15 Busan, Republic of Korea Welcome Message Dear Friends and Colleagues, On behalf of the Organizing
More informationFujifilm s Initiatives in Regenerative Medicine
Fujifilm s Initiatives in Regenerative Medicine Shigetaka Komori Chairman and CEO FUJIFILM Holdings Corporation March 30, 2015 Priority Business: Healthcare Expand business with focus on six core business
More informationChapter 8 Cell Diversity
Chapter 8 Cell Diversity Mr. C. Biology 1 Future? Chapter 8 Cell Diversity Cells, Tissues, Organs and Systems Cells have different shapes because they have different jobs to do. A nerve cell is very different
More informationCollagen Solutions Plc
Collagen Solutions Plc Jamal Rushdy, CEO Growth & Innovation Forum 2017 January 2017 Disclaimer This presentation is incomplete without reference to, and should be viewed solely in conjunction with the
More informationREMEDiE Project London 7-8 May 2009 European Policies and Priorities for Stem Cell Research
REMEDiE Project London 7-8 May 2009 European Policies and Priorities for Stem Cell Research Charles Kessler European Commission DG Research, Health Directorate Outline of presentation Main features of
More informationTissue Engineering and the Brain. Susan Perry Bioengineering Program Lehigh University
Tissue Engineering and the Brain Susan Perry Bioengineering Program Lehigh University ...all the most acute, most powerful, and most deadly diseases, and those which are most difficult to be understood
More informationOverview of USP Efforts to Identify Naming Schemes for Tissues and Tissue-Based Products
Quality Standards for Medicines, Supplements, and Food Ingredients throughout the World Overview of USP Efforts to Identify Naming Schemes for Tissues and Tissue-Based Products Darin Weber, Ph.D., Vice-Chair
More informationWhat Are Stem Cells? Where Are These Stem Cells?
While stem cell therapies may seem to have appeared overnight, they have been practiced for some time prior to the recent burst in new applications and stem cell sources. The most recent developments in
More informationBioreactors in tissue engineering
Bioreactors in tissue engineering S. Swaminathan Director Centre for Nanotechnology & Advanced Biomaterials School of Chemical & Biotechnology SASTRA University Thanjavur 613 401 Tamil Nadu Joint Initiative
More informationInsight to Gene Techno Science Co.,Ltd
Unlimited drug discovery from the beginning Ticker symbol: 4584 Insight to Gene Techno Science Co.,Ltd November 2017 2 Corporate Overview Chief Executive Founded March 2001 Masaharu Tani, President Listed
More informationCloning. 1. What is cloning: Natural and artificial 2. Cloning of what? 3. Embryonic development of multi-cellular organisms:
Cloning 1. What is cloning: Natural and artificial 2. Cloning of what? 3. Embryonic development of multi-cellular organisms: cell division, morphogenesis, differentiation 2. Plant cloning 3. Animal cloning
More informationSouth Carolina Donor Registry Q & A
South Carolina Donor Registry Q & A How do I become a registered organ and tissue donor? There are several ways to register your legal consent to be a donor: 1.) At any SCDMV office or on the SCDMV web
More informationRegeneration of spinal cord injury (SCI) : What we know so far. By: Kendra Michaud
Regeneration of spinal cord injury (SCI) : What we know so far By: Kendra Michaud INTRODUCTION BACKGROUND/IMPACT Neerumalla, Dr. Ravali. Spinal Cord Injury - Causes, Symptoms, Diagnosis, Treatment & Prevention.
More informationAlliqua BioMedical Investor Presentation August 2017 NASDAQ: ALQA
Alliqua BioMedical Investor Presentation August 2017 NASDAQ: ALQA Forward Looking Statements Safe Harbor Statement This presentation contains forward-looking statements. Forward-looking statements are
More information#SIS25th. 25th Annual Meeting Slides
25th Annual Meeting Slides Stem Cell for Spine Care - From dish to disc Wenchun Qu, MD, PhD Mayo Clinic Rochester Disclosures ØConsultant, DePuy Synthes ØBoard of Directors, American Academy of Regenerative
More informationThe New News in Stem Cell Research Andrés Bratt-Leal, PhD 12/1/2017
The New News in Stem Cell Research Andrés Bratt-Leal, PhD 12/1/2017 Cell Therapy and Parkinson s Disease Very specific neural degeneration >50% of DA neurons are gone by diagnosis 1 million in the USA,
More informationStem Cells Canadian Perspective
Stem Cells Canadian Perspective John Laffey Critical Illness and Injury Research Centre, Keenan Research Centre, St Michael s Hospital. Departments of Anesthesia, Physiology and Interdepartmental Division
More informationGene therapy. Findings by Alert
Gene therapy Published Mar 21, 2000 Version 1 Findings by Alert Research in gene therapy has increased dramatically during the past 15 years, particularly in the United States. The research has encompassed
More informationFundamental properties of Stem Cells
Stem cells Learning Goals: Define what a stem cell is and describe its general properties, using hematopoietic stem cells as an example. Describe to a non-scientist the current progress of human stem cell
More informationSupplemental Information. 1. Patent Search Methodology
Supplemental Information 1. Patent Search Methodology Thomson Innovation and Thomson Data Analyzer software were utilized to perform patent data mining. The search includes both granted patents and published
More informationHCT/P Regulation vs 361 Products
HCT/P Regulation - 351 vs 361 Products Presented by: Paul Gadiock February 15, 2017 Arent Fox LLP Washington, DC New York, NY Los Angeles, CA San Francisco, CA 1 Presentation Overview Introduction Public
More informationNanotechnology and Advanced Materials for more effective Healthcare
Nanotechnology and Advanced Materials for more effective Healthcare This challenge taps into the potential of nanotechnologies and advanced materials to enable more effective therapies and diagnostics
More informationHorizon 2020 funding opportunities for Regenerative Medicine ( ) Rudolf Fryček, PhD.
Horizon 2020 funding opportunities for Regenerative Medicine (2018-2020) Rudolf Fryček, PhD. Disclaimer: Any information mentioned is preliminary only, always consult the official documents. 1 Outline
More informationStem Cells. Part 1: What is a Stem Cell? STO Stem cells are unspecialized. What does this mean?
STO-120 Stem Cells Part 1: What is a Stem Cell? Stem cells differ from other kinds of cells in the body. When a stem cell divides by mitosis, each new cell has the potential to either remain a stem cell
More informationAlliance for Regenerative Medicine
Alliance for Regenerative Medicine Michael Werner Executive Director Alliance for Regenerative Medicine ARM s Focus & Role As the leading global advocate for the regenerative medicine and advanced therapies
More informationOpportunities for industry/smes in EU-funded health research
Opportunities for industry/smes in EU-funded health research Stéphane Hogan, M.Sc, MBA Head of Unit Applied Genomics and Biotechnology for Health DG Research - European Commission 1 Paris, 31 May 2005
More informationStem Cells and Regenerative Medicine
Q 0 Stem Cells and Regenerative Medicine Technologies and capabilities to add value to your company Differentiation HA-PPS for cartilage Parallel culture optimisation Stem Cell Therapies Fetal EPCs and
More informationMolecular Diagnostics
Molecular Diagnostics Part II: Regulations, Markets & Companies By Prof. K. K. Jain MD, FRACS, FFPM Jain PharmaBiotech Basel, Switzerland May 2018 A Jain PharmaBiotech Report A U T H O R ' S B I O G R
More informationMedical Sensors Market Research Report- Global Forecast to 2022
Report Information More information from: https://www.marketresearchfuture.com/reports/2038 Medical Sensors Market Research Report- Global Forecast to 2022 Report / Search Code: MRFR/HC/1506-HCRR Publish
More informationFunctional Assessment and Clinical Outcome
Tissue Engineering Functional Assessment and Clinical Outcome STEVEN A. GOLDSTEIN Orthopaedic Research Laboratories, Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan 48109,
More informationSpecial Report. medicine? Peter Marks, M.D., Ph.D., and Scott Gottlieb, M.D.
The new england journal of medicine Special Report Balancing Safety and Innovation for Cell-Based Regenerative Medicine Peter Marks, M.D., Ph.D., and Scott Gottlieb, M.D. Regenerative medicine is a field
More information2016 North American Cell Therapeutics Technology Innovation Award
2016 North American Cell Therapeutics Technology Innovation Award 2016 Contents Background and Company Performance... 3 Industry Challenges... 3 Technology Attributes... 3 Conclusion... 8 Significance
More informationIN VITRO TOXICITY TESTING: TECHNOLOGIES AND GLOBAL MARKETS
IN VITRO TOXICITY TESTING: TECHNOLOGIES AND GLOBAL MARKETS PHM017E January 2014 Robert Hunter Project Analyst ISBN: 1-56965-661-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationStem cells and motor neurone disease
Stem cells and motor neurone disease F Stem cell research has fuelled hope of a treatment for a variety of conditions. This information sheet explains what these cells are and includes details of the current
More informationANAT 2341 Embryology Lecture 18 Stem Cells
ANAT 2341 Embryology Lecture 18 Stem Cells 29 September 2010 Dr Antonio Lee Neuromuscular & Regenera
More informationNPTEL Biotechnology Tissue Engineering. Stem cells
Stem cells S. Swaminathan Director Centre for Nanotechnology & Advanced Biomaterials School of Chemical & Biotechnology SASTRA University Thanjavur 613 401 Tamil Nadu Joint Initiative of IITs and IISc
More informationCell and Gene Therapy Catapult preclinical database
Cell and Gene Therapy Catapult preclinical database The UK Preclinical Database covers preclinical research activity concerning cell, gene and other advanced therapies that the Cell and Gene Therapy Catapult
More informationWHAT THE DATA HAS TO SHOW: How Shifting Procedural Site of Service Affects Competitive Strategy in the Orthopedic Device Industry
14 th Annual Spine, Orthopedic and Pain Management-Driven ASC Conference + The Future of Spine WHAT THE DATA HAS TO SHOW: How Shifting Procedural Site of Service Affects Competitive Strategy in the Orthopedic
More informationleading the way in research & development
leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and
More informationHolland Innovation Network Team Boston: Walter de Wit Julia Knoeff
Holland Innovation Network Team Boston: Walter de Wit Julia Knoeff Boston and Cambridge in Massachusetts are innovation-focused hubs with world-leading universities such as Harvard, Boston University and
More information2013 Regenerative Medicine State of the Industry Briefing. January 8, 2013 Geoff MacKay, Chairman, ARM
2013 Regenerative Medicine State of the Industry Briefing January 8, 2013 Geoff MacKay, Chairman, ARM The Aging Global Population In the U.S., between 2010 and 2030 there will be a ~80% increase in the
More informationDevelopment Stage of Therapeutic Vaccines: The Regulator s View
Development Stage of Therapeutic Vaccines: The Regulator s View Thomas Hinz Head, Section Therapeutic Vaccines Paul Ehrlich Institute, Germany thomas.hinz@pei.de 1 DISCLAIMER This is the personal views
More informationANAT 3231 Cell Biology Lecture 21 Stem Cells
ANAT 3231 Cell Biology Lecture 21 Stem Cells Outline What are Stem Cells? Totipotency - Pluripotency - Multipotency What are different sources of Stem Cells? Embryonic vs Adult Pros and Cons for each type
More informationCELL-BASED ASSAYS: TECHNOLOGIES AND GLOBAL MARKETS
CELL-BASED ASSAYS: TECHNOLOGIES AND GLOBAL MARKETS BIO080B April 2014 Usha Nagavarapu Project Analyst ISBN: 1-56965-794-7 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationScaffolding Materials for Tissue Engineering. Parisa Bahrami, Hailun(Helen) Huang 1
Scaffolding Materials for Tissue Engineering Parisa Bahrami, Hailun(Helen) Huang 1 Content What is tissue scaffolding History of tissue scaffolding Types of tissue scaffolding Materials used in tissue
More informationNatural Fibers and Innovative
Natural Fibers and Innovative Biomaterials i for Medical lapplications Dr. Michael Wöltje 33rd International Cotton Conference Bremen, 17.03.2016 Classification of textile fibers Textile fibers Natural
More informationBIOTECHNOLOGY. Unit 8
BIOTECHNOLOGY Unit 8 PART 1 BASIC/FUNDAMENTAL SCIENCE VS. APPLIED SCIENCE! Basic/Fundamental Science the development and establishment of information to aid our understanding of the world.! Applied Science
More informationIntroduction to Cell- Biomaterial Engineering!
Introduction to Cell- Biomaterial Engineering! Module 3, Lecture 1! 20.109 Spring 2010! Topics for Lecture 1!! Introduction to tissue engineerin! motivation"! basic principles + examples"! Introduction
More informationBackground. Background. Background. Background. Background 3/4/2013
3/4/213 Human Very Small Embryonic-like Stem Cells (s) Capacity to Regenerate Bone Tissue: A Potential Cell-based Therapy for Autogenous Bone Grafting Aaron M. Havens, DMD Need to discover an improved
More informationRecent Progress in ips Cell Research and Application
Recent Progress in ips Cell Research and Application Shinya Yamanaka, M.D., Ph.D. Center for ips Cell Research and Application (CiRA), Kyoto University, Japan Takeda - CiRA Joint Program, Shonan, Japan
More informationSubj: ESTABLISHMENT OF A HUMAN CELL, TISSUE, AND CELLULAR AND TISSUE-BASED PRODUCTS MANAGEMENT PROGRAM
DEPARTMENT OF THE NAVY BUREAU OF MEDICINE AND SURGERY 7700 ARLINGTON BOULEVARD FALLS CHURCH, VA 22042 IN REPLY REFER TO ` BUMEDINST 6300.21 BUMED-M3 BUMED INSTRUCTION 6300.21 From: Chief, Bureau of Medicine
More informationFuture implications of regenerative medicine on assisted reproductive technology. Regenerative medicine. History of Regenerative medicine
Gyndolomiti: 2nd Congress on Gynaecology and Obstetrics February 1 6, 2015 St. Kassian / South Tyrol Regenerative medicine Future implications of regenerative medicine on assisted reproductive technology
More informationSIRRIS. Bioprinting: markets and opportunities. Grégory Nolens. QED AM in Medical November 4th 2014
SIRRIS Bioprinting: markets and opportunities Grégory Nolens QED AM in Medical November 4th 2014 Collective centre of the technology industry Non profit organization Industry owned 4,700 industrial interventions
More informationChina-EU Competition Week: Abbott's Acquisition of St. Jude Medical
China-EU Competition Week: Abbott's Acquisition of St. Jude Medical Anti-monopoly Bureau, MOFCOM Tang Yu March 2017 Part I: basic information of the case Part II: definition of relevant markets and competitive
More informationRegenerative medicine approaches to the treatment of cardiovascular disease
Regenerative medicine approaches to the treatment of cardiovascular disease Author: Noah Weisleder, Ph.D. Abstract: Ischemic heart disease related myocardial infarction (MI) remains the leading cause of
More informationBIOMEDICAL ENGINEERING (BMED)
Biomedical Engineering (BMED) 1 BIOMEDICAL ENGINEERING (BMED) BMED 1000. Introduction to Biomedical Engineering. 1 Credit Hour. An introduction to the field of biomedical engineering, with an emphasis
More informationStem Cells: A Primer National Institutes of Health
Stem Cells: A Primer National Institutes of Health I. INTRODUCTION Research on stem cells is advancing knowledge about how an organism develops from a single cell and how healthy cells replace damaged
More informationFreshman/Sophomore Junior Senior
Freshman/Sophomore Junior Senior Course Recommendations Mathematics (6 courses) MA 1021 MA 1024 (Calculus I) (Calculus IV) MA 1022 MA 2051 (Calculus II) (Differential Equations) MA 1023 MA 2611 (Calculus
More informationLisa Griffin (BSc Hons Biology), David Hughes August 2013
Title Authors Contact Target level Publication date Lisa Griffin (BSc Hons Biology), David Hughes Maggy.fostier@manchester.ac.uk KS4 science, GCSE August 2013 Activity Length Content related to the GCSE
More informationShould Embryonic Stem Cell Research be Permitted to Continue? Over the past few years a debate has been going on over the moral implications of
Courtesy of Christopher Waits. Used with permission. Waits 1 Should Embryonic Stem Cell Research be Permitted to Continue? Over the past few years a debate has been going on over the moral implications
More informationGenetic Basis of Development & Biotechnologies
Genetic Basis of Development & Biotechnologies 1. Steps of embryonic development: cell division, morphogenesis, differentiation Totipotency and pluripotency 2. Plant cloning 3. Animal cloning Reproductive
More informationInVivo Therapeutics. Developing Innovative Products for Spinal Cord Injury
1 Developing Innovative Products for Spinal Cord Injury 2 Forward-Looking Statements Before we begin, we would like to remind everyone that during our presentation, we will be making forward-looking statements
More informationStem Cell Principle -
Effective Date: 31.10.2017 Doc ID: 20290214 Version: 1.0 Status: Approved Planned Effective Date: 31-Oct-2017 00:00 CET (Server Date) Stem Cell Principle - Rationale Research on human stem cells and their
More informationRegulatory Updates on Cellular Therapy Products in Japan
Regulatory Updates on Cellular Therapy Products in Japan Daiju Okuda, Ph.D. Principle Reviewer Office of Cellular and Tissue-based Products Pharmaceuticals and Medical Devices Agency (PMDA), Japan September
More informationSupplemental Information. Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry. Leigh Turner and Paul Knoepfler
Cell Stem Cell, Volume 19 Supplemental Information Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry Leigh Turner and Paul Knoepfler Supplemental Information Search approach We used
More information4006: Cellular Therapy Infusion
4006: Cellular Therapy Infusion Registry Use Only Sequence Number: Date Received: Key Fields CIBMTR Center Number: Event date: / / CIBMTR Form 4006 revision 1 (page 1 of 9). Last Updated July, 2016. If
More informationStem Cells for the Future Treatment of Parkinson's Disease
Home Stem Cell Basics Stem Cell Basics I. Introduction II. III. IV. What are the unique properties of all stem cells? What are embryonic stem cells? What are adult stem cells? V. What are the similarities
More informationThe Military Biomaterials Roadmap: Gap Analysis and CeMBR
The Military Biomaterials Roadmap: Gap Analysis and CeMBR David Devore, Ph.D. COO, Center for Military Biomaterials Research (CeMBR) Rutgers, the State University of New Jersey 145 Bevier Road Piscataway,
More informationNANOTECHNOLOGY IN MEDICAL APPLICATIONS: THE GLOBAL MARKET
NANOTECHNOLOGY IN MEDICAL APPLICATIONS: THE GLOBAL MARKET HLC069C September 2015 Paul Evers Project Analyst ISBN: 1-62296-144-7 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationStem Cell Services. Driving Innovation for Stem Cell Researchers
Driving Innovation for Stem Cell Researchers Stem Cell Services Partner with us and have access to the most advanced and comprehensive stem cell services available today. 675 W. Kendall St. Cambridge,
More informationProduction Assistance for Cellular Therapies PACT
Production Assistance for Cellular Therapies PACT Traci Heath Mondoro, PhD NHLBI Bethesda, Maryland Renewed PACT Program Renewed January 15, 2010 Scope and size expanded Cell Processing Facilities (CPFs)
More informationIt is theoretically possible to engineer organs such as livers, kidneys, breasts and intestines.
SPECIAL REPORT GROWING NEW Researchers have taken the first steps toward creating semisynthetic, living organs that can be used as human replacement parts by David J. Mooney and Antonios G. Mikos Every
More informationOPHTHALMIC THERAPEUTIC DRUGS: TECHNOLOGIES AND GLOBAL MARKETS
OPHTHALMIC THERAPEUTIC DRUGS: TECHNOLOGIES AND GLOBAL MARKETS PHM031D July 2015 Dr. Cheryl Lee Barton Project Analyst ISBN: 1-62296-123-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
More informationMesenchymal Stromal/Stem Cells
Mesenchymal Stromal/Stem Cells Peiman Hematti, M.D. Department of Medicine Financial Disclosure: Consulting Fees from Celgene Cellular Therapeutics in 2011 & 2012 1 Caplan used the term Mesenchymal Stem
More informationAdipose rabbit mesenchymal stem cells for the treatment of the chronic scar tissue of the vocal cords
Adipose rabbit mesenchymal stem cells for the treatment of the chronic scar tissue of the vocal cords Dr. Vasiliki E Kalodimou, Head of Flow Cytometry-Research and Regenerative Medicine Department, IASO-Maternity
More information